STATE STREET CORP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$520,115
-49.9%
521,000
-50.0%
0.00%
Q4 2022$1,038,120
+105.2%
1,042,000
+100.0%
0.00%
Q3 2022$506,000
-0.6%
521,0000.0%0.00%
Q2 2022$509,000
+6.0%
521,0000.0%0.00%
Q1 2022$480,000
-67.1%
521,000
-65.7%
0.00%
Q4 2021$1,457,000
+5.9%
1,521,0000.0%0.00%
Q3 2021$1,376,000
-85.9%
1,521,000
-85.7%
0.00%
-100.0%
Q2 2021$9,766,000
+10.2%
10,663,0000.0%0.00%0.0%
Q1 2021$8,864,000
+7.0%
10,663,000
+3.9%
0.00%0.0%
Q4 2020$8,281,000
+10.0%
10,263,000
+10.8%
0.00%0.0%
Q3 2020$7,531,000
-13.5%
9,263,000
-18.5%
0.00%0.0%
Q2 2020$8,705,000
-20.9%
11,363,000
-15.6%
0.00%0.0%
Q1 2020$11,004,000
-22.4%
13,463,000
-2.8%
0.00%0.0%
Q4 2019$14,189,000
+19.6%
13,855,000
+1.1%
0.00%0.0%
Q3 2019$11,860,000
-3.4%
13,700,000
+1.1%
0.00%0.0%
Q2 2019$12,275,000
-6.7%
13,550,000
+2.7%
0.00%0.0%
Q1 2019$13,151,000
+1.6%
13,200,000
-4.7%
0.00%0.0%
Q4 2018$12,943,000
-12.5%
13,850,000
-5.0%
0.00%0.0%
Q3 2018$14,793,000
+4.5%
14,575,000
-8.0%
0.00%0.0%
Q2 2018$14,156,000
+17.9%
15,850,000
+7.3%
0.00%0.0%
Q1 2018$12,003,000
+4.7%
14,775,000
+5.3%
0.00%0.0%
Q4 2017$11,467,000
+19.9%
14,025,000
+15.2%
0.00%0.0%
Q3 2017$9,567,00012,175,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Birch Grove Capital LP 15,003,000$13,500,0006.56%
PenderFund Capital Management Ltd. 9,605,000$10,735,0002.51%
Silver Point Capital L.P. 38,808,000$34,151,0001.87%
Benefit Street Partners LLC 5,045,000$4,440,0001.69%
Context Capital Management, LLC 11,279$10,168,0000.94%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$51,920,0000.92%
DeepCurrents Investment Group LLC 30,292,000$27,169,0000.81%
Saltoro Capital, LP 1,800,000$1,623,0000.66%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 20,481,000$18,638,0000.52%
Kohlberg Kravis Roberts & Co. L.P. 64,548,000$58,191,0000.24%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders